Related references
Note: Only part of the references are listed.Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
Matthew Austin et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Effects of Bazedoxifene on Bone Mineral Density, Bone Turnover, and Safety in Postmenopausal Japanese Women With Osteoporosis
Akira Itabashi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Relationship between bone mineral density changes and risk of fractures among patients receiving calcium with or without vitamin D supplementation: a meta-regression
V. Rabenda et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
S. Vasikaran et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial
T. J. de Villiers et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis
Claus Christiansen et al.
BMC MUSCULOSKELETAL DISORDERS (2010)
Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis
Santiago Palacios
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Long-term fracture prediction by bone mineral assessed at different skeletal sites
L. Joseph Melton et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Vertebral fracture assessment using a semiquantitative technique
Harry K. Genant et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years
O. Bruyere et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX®
John A. Kanis et al.
BONE (2009)
Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women
Olivier Bruyere et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2009)
Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis
Pierre D. Delmas et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis
Jennifer A. Harvey et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2009)
Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis
JoAnn V. Pinkerton et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2009)
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
Stuart L. Silverman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Biomarkers for osteoporosis management - Utility in diagnosis, fracture risk prediction and therapy monitoring
Patrick Garnero
MOLECULAR DIAGNOSIS & THERAPY (2008)
Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study
Paul D. Miller et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate
O. Bruyere et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate
Olivier Bruyere et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?
E. Seeman
BONE (2007)
Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis
Peiqi Chen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2006)
Monitoring osteoporosis therapy: Bone mineral density, bone turnover markers, or both?
SL Bonnick et al.
AMERICAN JOURNAL OF MEDICINE (2006)
Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis
DC Bauer et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Compliance with osteoporosis medications
DH Solomon et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial
RD Chapurlat et al.
OSTEOPOROSIS INTERNATIONAL (2005)
Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis
PQ Chen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Biochemical markers of bone turnover are influenced by recently sustained fracture
KJ Obrant et al.
BONE (2005)
Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy
PD Delmas et al.
BONE (2004)
Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk
JY Reginster et al.
BONE (2004)
Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: Some issues with meta-analyses
PD Delmas et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate
NB Watts et al.
JOURNAL OF CLINICAL DENSITOMETRY (2004)
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial
DC Bauer et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes
S Boonen et al.
JOURNAL OF INTERNAL MEDICINE (2004)
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate
R Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents
MC Hochberg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs
SR Cummings et al.
AMERICAN JOURNAL OF MEDICINE (2002)
Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy
S Sarkar et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
A method to assess the proportion of treatment effect explained by a surrogate endpoint
ZQ Li et al.
STATISTICS IN MEDICINE (2001)
Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis
NH Bjarnason et al.
OSTEOPOROSIS INTERNATIONAL (2001)
Evaluation of changes in trabecular bone architecture and mechanical properties of minipig vertebrae by three-dimensional magnetic resonance microimaging and finite element modeling
B Borah et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
Antifracture efficacy of antiresorptive agents are related to changes in bone density
RD Wasnich et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
Trabecular bone microarchitecture, bone mineral density, and vertebral fractures in male osteoporosis
E Legrand et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
Share Paper
